Vaccine shortage will affect all eligible groups
The two private vaccine manufacturers — Serum Institute and Bharat Biotech — are required to supply 50% of vaccine produced to the Central government and the balance to State governments…
Category: Communicable disease
Covaxin offers protection against double mutant (B.1.617) variant
A preprint of the study carried out by ICMR and Bharat Biotech researchers has been posted in biorXiv. Preprints are yet to be peer-reviewed and published in medical journals. So…
India sets a dangerous precedent with COVID-19 vaccination programme
A large percentage of those aged 18-44 years does not have the resources to pay for vaccines and hence will fall through the cracks. So, the States will have to…
Can vaccination of all adults slow down the second wave?
While Maharashtra is still reporting the most cases daily, there has been a slip dip in the last few days. It is a bit early to say if the second…
Serum refuses to address differential pricing for Central and State governments
The statement tried to address the controversy over whether the price of the vaccines at Rs 600 (nearly $8) per dose for private hospitals was more than their costs when they were…
India will have 8-10 lakh cases a day when second wave peaks in mid-May, says Bhramar Mukherjee
Since April 1, the number of daily cases has been accelerating at a rapid speed. Can it be any reason other than more infectious variants? We have to be cautious…
Zydus Cadila’s antiviral drug for moderate COVID-19 disease gets emergency use approval
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster…
Preliminary study shows Covishield protects against double mutant variant
“Both Covishield vaccinated sera and convalescent sera were found to offer protection against the double mutant variant (B.1.617),” says Dr. Rakesh Mishra, Director of CCMB. “This is only a preliminary…
